KalVista Stock Soars on $1.9B Chiesi Acquisition Deal

Chiesi Group to Acquire KalVista in $1.9B Deal

Italy’s Chiesi Group has announced a definitive agreement to acquire KalVista Pharmaceuticals for $1.9 billion, including debt. The news caused KalVista's stock to surge 38.6% in premarket trading on Monday.

Overview of the Acquisition

Under the terms of the agreement, Chiesi will pay $27 per share in cash for KalVista. This price represents a significant 36% premium over KalVista’s average share price during the past month. The acquisition provides Chiesi with control over Ekterly, KalVista’s oral, on-demand treatment for the rare genetic condition hereditary angioedema.

Market Reaction and Future Outlook

KalVista shares reacted positively to the news, climbing to $26.66 in premarket trading. The transaction is anticipated to close in the third quarter of 2026, pending necessary regulatory approvals and other standard closing conditions.

Summary

The acquisition marks a strategic move by Chiesi to expand its portfolio with a promising treatment for a rare disease. For KalVista shareholders, the deal offers a substantial premium, and the market's focus now shifts to the upcoming regulatory approval process.

FAQ

Q: Why is Chiesi acquiring KalVista?
A: Chiesi is acquiring KalVista to gain control of its drug Ekterly, an oral treatment for the rare genetic condition hereditary angioedema.

Q: What was the immediate effect on KalVista's stock?
A: KalVista (KALV) shares surged 38.6% to $26.66 in premarket trading following the announcement.

Source: Investing.com